Sunovion Pharmaceuticals Inc. Announces Publication of Two Pivotal Studies Supporting FDA Approval of Latuda® (lurasidone HCl) as Monotherapy and Adjunctive Therapy in Adult Patients With Bipolar Depression in The American Journal of Psychiatry

Published: Nov 01, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. today announced that the results of two pivotal trials supporting the U.S. Food and Drug Administration (FDA) approval of Latuda® (lurasidone HCl) for the treatment of adult patients with major depressive episodes associated with bipolar I disorder (bipolar depression), both as monotherapy and as adjunctive therapy with lithium or valproate, were published online in The American Journal of Psychiatry (AJP) on October 30, 2013.1,2,3 The full studies and accompanying editorial commentary can be found at AJP in Advance, the website for the publication:

Help employers find you! Check out all the jobs and post your resume.

Back to news